A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

Annals of Oncology - Tập 30 - Trang v488-v489 - 2019
A. Spreafico1, F. Janku2, J.A. Rodon2, A.W. Tolcher3, S.R. Chandana4, M. Oliva1, S. Musalli5, L. Knauss5, M. Kragh5, L. Alifrangis5, C. Fröhlich5, M.C. Melander5, T. Blondal5, M.W. Pedersen5, J. Lantto5, D. Wood6, P.I. Nadler6, I.D. Horak5, L.L. Siu1, N. Lakhani4
1Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada
2Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Clinical Research, NEXT Oncology, San Antonio, TX, USA
4Developmental Therapeutics, START - Midwest, Grand Rapids, MI, USA
5Preclinical and Clinical Development, Symphogen A/S, Ballerup, Denmark
6Medical Research, Nadler Pharma Associates, Randolph, NJ, USA

Thông tin
Thông tin xuất bản

Annals of Oncology

Tập 30

v488-v489

Thông tin tác giả